BridgeBio Pharma, Inc.: updates and filings

BBIONASDAQHealthcare · Pharmaceutical Preparations

Price

$77.36

November 16, 2026Market cap $15.0B

What Ploutos Investor adds for BridgeBio Pharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 80 daysAround Feb 5, 2027 · for Q4 2026

last Oct 29, 2026next Feb 5, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 24, 2026 latest annualOct 29, 2026 latest quarterly
  • Nov 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Results of operations
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 13, 2026Other material events
    Form8-K
  • Aug 31, 2026Other material events
    Form8-K
  • Aug 17, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 17, 2026Material agreement entered, other material events
    Form8-K
  • Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 10, 2026Results of operations
    Form8-K
  • Aug 3, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 24, 2026Shelf registration for future offerings
    FormS-3ASR
  • Jul 24, 2026Shares registered for employees
    FormS-8
  • Jul 22, 2026Other material events
    Form8-K
  • Jul 10, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jul 2, 2026Material agreement entered, unregistered sale of shares, change to shareholders' rights, amended articles or bylaws, Regulation FD disclosure
    Form8-K
  • Jun 26, 2026Officer or director change, shareholder vote
    Form8-K
  • May 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 27, 2026Other material events
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 13, 2026Other material events
    Form8-K
  • May 8, 2026Material agreement entered, material agreement ended
    Form8-K
  • May 8, 2026Shelf registration for future offerings
    FormS-3ASR
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 19, 2018.

The full analysis

What do BridgeBio Pharma's filings show?

The filings are where every one of BridgeBio Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.